The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1649
May 2, 2022
View Complete Issue         Table of Contents 2019 
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
May 2, 2022 (Issue: 1649)
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration
Article code: 1649c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.